Cerebral Infarction Drugs Market Size

  • Report ID: 3382
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Cerebral Infarction Drugs Market Size

Cerebral Infarction Drugs Market size was valued at USD 7.61 billion in 2024 and is expected to reach USD 21.2 billion by 2037, expanding at around 8.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cerebral infarction drugs is assessed at USD 8.64 billion.
 

The growth of the market can be attributed to the increasing frequency of cerebrovascular disease, coupled with the surging prevalence of ischemic strokes throughout the world. For instance, the frequency of ischemic strokes increased to over 7.8 million new ischemic strokes by 2019, which denotes ischemic strokes accounted for more than 63% of all incident strokes worldwide. Further, the worldwide growing ratio of the geriatric population, along with an increase in hypertension rate is another significant factor anticipated to fuel the growth of the global cerebral infarction drugs market over the forecast period.

 In addition to these, factors that are believed to fuel the market growth of cerebral infarction drugs include the rise in population throughout the world as the increasing population has been affected by numerous types of disorders and cerebral infarction can affect any person of any age group. According to the World Bank report, in 2021, the total population of the world has expanded to 7.89 billion. Additionally, the growing awareness in people regarding the cerebrovascular disease, along with the surging investment in developing novel drugs is also estimated to spur market growth throughout the forecast period.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3382
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of cerebral infarction drugs is assessed at USD 8.64 billion.

The cerebral infarction drugs market size was valued at USD 7.61 billion in 2024 and is expected to reach USD 21.2 billion by 2037, expanding at around 8.2% CAGR during the forecast period i.e., between 2025-2037. Worldwide growing prevalence of sedentary lifestyle, rising cases of arterial embolism, and rising ratio of clinical trials and their positive outcomes will boost the market growth.

North America industry is poised to hold largest revenue share of 50% by 2037, propelled by increasing frequency of cerebrovascular disease amongst several people, driven by sedentary lifestyle of individuals.

The major players in the market are Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Edwards Lifesciences Corporation, Daiichi Sankyo Company, Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample